Yu Tian

Dr. Yu Tian

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
PYPeng Yin
Peng Yin
ZSZhaoliang Su
Zhaoliang Su
XSXiaozheng Shu
Xiaozheng Shu
ZDZhifeng Dong
Zhifeng Dong
YTYu Tian
Yu Tian

12 December 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
PYPeng Yin
Peng Yin
HJHaiqiang Jiang
Haiqiang Jiang
XJXiaoyun Ji
Xiaoyun Ji
LXLin Xia
Lin Xia
ZSZhaoliang Su
Zhaoliang Su
YTYu Tian
Yu Tian

6 May 2022 in Frontiers in Human Neuroscience
Verified
Journal Article
Open access
JWJiaming Wang
Jiaming Wang
YTYu Tian
Yu Tian
Xin ShiXin Shi
Xin Shi
ZFZhaohai Feng
Zhaohai Feng
LJLei Jiang
Lei Jiang
YHYujun Hao
Yujun Hao
Background: The past four decades have seen the growing use of tissue or cell transplants in Parkinson’s disease (PD) treatment. Parkinson’s cell therapy is a promising new treatment; however, efficacy of cell transplantation for Parkinson’s disease are entirely unclear.Objective: To conduct a meta-analysis and a systematic review of the efficacy of cell therapy in patients with PD.Methods: A systematic literature review and meta-analysis of 10 studies were performed to assess the efficacy of cell therapy in Parkinson’s patients. To achieve this, we compared the change in Unified Parkinson’s Disease Rating Scale (UPDRS) II and III scale scores to baseline and assessed the incidence of transplant-related adverse events. The MINORS score and the I2 index were applied to evaluate the quality of studies between-study heterogeneity, respectively.Results: The literature search yielded 10 articles (n = 120). The improvement in motor function based on the UPDRSIII assessment was −14.044 (95% CI: −20.761, −7.327) (p < 0.001), whereas improvement in daily living ability based on the UPDRSII assessment was −5.661 (95% CI: −7.632, −3.689) (p < 0.001).Conclusion: The present findings demonstrate important clues on the therapeutic effect of cell therapy in alleviating motor impairment and daily living ability in PD patients.

14 July 2026 in Cytokine
Verified
Journal Article
Closed access
QHQining Huang
Qining Huang
JTJingwen Tang
Jingwen Tang
XSXiaozheng Shu
Xiaozheng Shu
ZSZhaoliang Su
Zhaoliang Su
YTYu Tian
Yu Tian

19 January 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
YTYu Tian
Yu Tian
YCYuwen Cao
Yuwen Cao
FLFang Liu
Fang Liu
LXLin Xia
Lin Xia
CWChao Wang
Chao Wang
Zhaoliang SuZhaoliang Su
Zhaoliang Su
In this study, we investigated the role of the non-canonical pyroptosis pathway in the progression of lethal sepsis. Our findings emphasize the significance of non-canonical pyroptosis in monocytes/macrophages for the survival of septic mice. We observed that inhibiting pyroptosis alone significantly improved the survival rate of septic mice, and the HMGB1 A box effectively suppressed this non-canonical pyroptosis, thereby enhancing the survival of septic mice. Additionally, our cell in vitro experiments further unveil that frHMGB1, originating from LPS-carrying histiocytes, enters macrophages via RAGE, resulting in the direct activation of caspase-11 and the induction of non-canonical pyroptosis. Notably, the A Box's competitive binding with LPS thereby impedes its entry into the cell cytosol. These findings reveal potential therapeutic strategies for slowing the progression of lethal sepsis by modulating the non-canonical pyroptosis pathway.

26 April 2026 in International Immunopharmacology
Verified
Journal Article
Closed access
CXChengchen Xie
Chengchen Xie
XSXiaozheng Shu
Xiaozheng Shu
YWYan Wu
Yan Wu
YTYu Tian
Yu Tian